According to a new report released by the American Cancer Society, deaths from cancer dropped 27% over the past 25 years, meaning an estimated 2.6 million fewer people died of the disease during that period. Researchers credit long-running efforts to reduce smoking, as well as advances in detection and treatment of cancer at earlier stages, when prognosis for recovery is generally better, for this tremendous achievement.
This is excellent news for patients and their family members, caregivers and others impacted by cancer.
Is this the end of the age of Apple? That was the question posed by Kara Swisher, editor at large for the technology news website Recode, in a column for The New York Times recently. Her piece was prompted by Apple’s announcement that it was going to miss its projected revenue by billions of dollars this quarter.
She wondered where the next great boom of innovation is going to come from. We would argue that the next great boom of innovation is already here – and has been for quite some time – in medical technology.
The International Consortium of Investigative Journalists (ICIJ) recently launched its latest campaign, which purports to investigate medical device safety. The “Implant Files,” however, is no more than a misguided attempt to stoke fear and doubt over the safety of medical devices that have saved and improved the lives of millions of Americans. In fact, while attempting to castigate advances in medicinal technology, the campaign itself recognizes that the data they use to support their coverage “is inconsistent and incomplete.”
Here’s the truth: nearly every American has benefited from the advancements of medical technology innovation in their life, from the NICU, to tools used during routine doctors’ visits, to hearing aids, to advanced surgical equipment, to pacemakers, to intraocular lenses, and replacement joints.
WASHINGTON, DC – Mark Leahey, President and CEO of the Medical Device Manufacturers Association (MDMA) issued the following statement today regarding the FDA’s release of their “Plan of Action for Implementation of 510(k) and Science Recommendations:”
“We commend FDA leadership and staff for working with various stakeholders in an open and constructive process to develop consensus proposals that improve patient access to safe and effective therapies. As more details are provided on specific recommendations, MDMA will submit additional comments to FDA to help make the regulatory process more efficient and effective.